SEC Tracker
Get the app

Kyntra Bio

KYNB

Listing: 2 notices since Apr 2026 (newest Oct 6)

Revenue −$1.5M (−209%), diluted EPS $2.96 in the quarter ended Jun 30, 2026, from a 10-Q filed .

Insiders No open-market insider buys or sells at Kyntra Bio in the last 90 days; 4 filings reported awards, option exercises, tax withholding or new insiders. Every trade

Next: earnings expected ~Nov 12; 10-Q expected ~Nov 12 (deadline Nov 16). Usually files the same day as earnings.

Get email alertsGet the app
Legal name
Kyntra Bio, Inc.
CIK
921299
Sector
Biotech and pharma
  • Cash and short-term investments$91.3MCash and short-term investments up $68.0M vs the Jun 2025 quarter
  • Operating burn, last quarter$4.0MBurn up $16.7M vs the Jun 2025 quarter
  • Shares outstanding4.0M+0% from 4.0M on Jul 31, 2025

From the 10-Q 0001193125-26-349183 on EDGAR

Major8-K filed

Kyntra Bio faces delisting threat

  • Received delisting notice from Nasdaq on Sep 30, 2026
  • Requested hearing to challenge delisting decision
  • Previously non-compliant with Nasdaq listing rules since Apr 2, 2026

Read the 8-K on EDGARTables over time

Cash runway and key numbers

About 10.2 quarters of cash at the average operating burn of the last 2 quarters, which would last to about Jan 2029.

Cash and short-term investments
$91.3M
Operating burn a quarter, average of the last 2 quarters
$8.9M

Operating burn by quarter: $13.9M in the Mar 2026 quarter, $4.0M in the Jun 2026 quarter; the runway uses their average, $8.9M. Last quarter’s burn was under half that average, so the average overstates the latest rate.

From the 10-Q 0001193125-26-349183 for the period ended Jun 30, 2026, as tagged in its XBRL. An estimate from reported figures, not a forecast or advice.

Last quarter’s operating cash flow is the 6-month total in 0001193125-26-349183 less the 3-month total in 0001193125-26-219374.

Every quarter as a table
Key numbers, last 8 quarters (— means no figure was tagged for that quarter; each share count is the one on the report's cover, with the cover date under it; share counts are as each report filed them, not adjusted for later reverse splits, so a fall of more than half between quarters is usually a reverse split)
Sep 24Dec 24Mar 25Jun 25Sep 25Dec 25Mar 26Jun 26
Cash and short-term investments$131M$50.5M$33.6M$23.4M$118M$89.0M$87.2M$91.3M
Quarterly burn$8.4M$30.5Mnonenone$1.8M$18.3M$13.9M$4.0M
Shares outstanding101Mas of Oct 31101Mas of Feb 28101Mas of Apr 304.0Mas of Jul 314.0Mas of Oct 314.0Mas of Feb 284.0Mas of Apr 304.0Mas of Jul 31
R&D$20.0M$6.9M$9.2M$5.9M$1.2M$7.3M$7.6M$6.8M

Every line item over time, with Excel and CSV export

Get an email when Kyntra Bio files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

What Kyntra Bio does

Products

  • FG-3246 In development

    A potential first-in-class antibody-drug conjugate targeting CD46 for the treatment of metastatic castration-resistant prostate cancer and potentially other cancers. Source

    Key ingredient: CD46

  • FG-3180 In development

    An associated CD46-targeted positron emission tomography biomarker and imaging agent for the treatment of metastatic castration-resistant prostate cancer. Source

    Key ingredient: CD46-targeted antibody

  • roxadustat Product

    An orally administered small molecule hypoxia-inducible factor prolyl hydroxylase inhibitor for the treatment of anemia in chronic kidney disease and lower-risk myelodysplastic syndromes. Source

    Sold in Europe, Japan, China, and numerous other countries

    • Food and Drug Administration: investigational Source

From the 10-K filed Mar 16, 2026, Item 1, Business (its first part). Open the filing. Each line links to the passage it restates. The company's own description, summarized; not investment advice.

All filings

Results, 8-Ks and Major or Notable filings come first, then registrations and share actions, then everything else, newest first. Routine filings are kept here unmarked; insider filings are summed up in one line.

Results, 8-Ks and key filings

  6. 2 more 8-K filings, Jun 15 to Jun 9
  10. 7 older filings, Mar 16 to May 12, 2025

No open-market insider buys or sells at Kyntra Bio in the last 90 days; 4 filings reported awards, option exercises, tax withholding or new insiders. Every KYNB insider trade

Other filings

Older filings on EDGAR

Listing compliance

0 open of 2 listing notices from 8-K item 3.01.

  • Oct 6, 2026 8-K item 3.01 notice; rule and cure date not stated, see the filing
  • Apr 9, 2026 8-K item 3.01 notice; rule and cure date not stated, see the filing

Dates and rules are as stated in each 8-K item 3.01 filing; a blank means the filing did not state one. Read the filing for the full terms. All open notices

Trading halts

No trading halts for KYNB since Feb 22, 2019, when SEC Tracker began reading the Nasdaq Trader feed.

Halt times and codes from the Nasdaq Trader trade halts feed, which lists Nasdaq and other exchange halts. Filings matched by SEC Tracker from EDGAR by company and time. Not investment advice. All recent halts

Fails-to-deliver: 164 shares on Aug 28, 2026, per SEC data

Coming up

  1. Earnings, expected
  2. 10-Q, expected (deadline Nov 16)

Stated dates are as each filing on EDGAR gives them; an expected date is estimated from the company's past filing dates, the same estimate as the top of the page. Not investment advice.

Kyntra Bio shares and listing

From the company's own filings; each row names its source. Not investment advice.

  • Shares outstandingas of Jul 31, 2026 (10-Q filed Aug 13)4Mwarrants, notes and options not read yet, so fully diluted is not known
  • Listing compliance8-K item 3.012 noticesstatus not stated, see the filings

Insider activity

No open-market insider buys or sells at Kyntra Bio in the last 90 days; 4 filings reported awards, option exercises, tax withholding or new insiders.

All KYNB insider trades